NCT07755826 Repotrectinib Post-Marketing Surveillance in Pediatric Patients With NTRK Fusion-Positive Tumors in Japan
| NCT ID | NCT07755826 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Bristol-Myers Squibb |
| Condition | NTRK Fusion-positive Solid Tumors |
| Study Type | OBSERVATIONAL |
| Enrollment | 20 participants |
| Start Date | 2025-11-20 |
| Primary Completion | 2034-04-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 20 participants in total. It began in 2025-11-20 with a primary completion date of 2034-04-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study will collect safety information during routine medical care for children and adolescents in Japan who have been diagnosed with NTRK fusion-positive advanced or recurrent solid tumors who start treatment with repotrectinib. The study will describe how often side effects occur during treatment, with special attention to central nervous system disorders, interstitial lung disease, and fractures.
Eligibility Criteria
Inclusion Criteria: * All pediatric NTRK fusion-positive, advanced or recurrent solid tumors patients (age 4 to \< 18) who received Repotrectinib for the approved indications at medical institutions in Japan during enrollment period (for 6 years after approval for this application) will be enrolled in this Post-Marketing Study. Exclusion Criteria: * Participants receiving repotrectinib for an off-label indication
Contact & Investigator
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
✉ Clinical.Trials@bms.com📞 855-907-3286
Bristol Myers Squibb
STUDY DIRECTOR
Bristol-Myers Squibb
Frequently Asked Questions
Who can join the NCT07755826 clinical trial?
This trial is open to participants of all sexes, aged 4 Years or older, up to 17 Years, studying NTRK Fusion-positive Solid Tumors. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07755826 currently recruiting?
Yes, NCT07755826 is actively recruiting participants. Contact the research team at Clinical.Trials@bms.com for enrollment information.
Where is the NCT07755826 trial being conducted?
This trial is being conducted at Minato-ku, Japan, Tokyo, Japan.
Who is sponsoring the NCT07755826 clinical trial?
NCT07755826 is sponsored by Bristol-Myers Squibb. The principal investigator is Bristol Myers Squibb at Bristol-Myers Squibb. The trial plans to enroll 20 participants.